RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oyster Point Pharma Stock

Oyster Point Pharma P/E 2024

Oyster Point Pharma P/E

-5.58

Ticker

OYST

ISIN

US69242L1061

WKN

A2PTTE

As of Oct 2, 2024, Oyster Point Pharma's P/E ratio was -5.58, a 0% change from the 0 P/E ratio recorded in the previous year.

The Oyster Point Pharma P/E history

Oyster Point Pharma Aktienanalyse

What does Oyster Point Pharma do?

Oyster Point Pharma Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. The company is headquartered in the San Francisco Bay Area and was founded in 2015. History: Oyster Point Pharma was founded by an experienced team of biologists and pharmaceutical experts. The company was supported by venture capital financing from leading venture capitalists. The founders' goal was to develop innovative therapies for eye diseases. In 2017, the company introduced a pipeline of therapies for various eye diseases based on the stimulation of tear flow, corneal nerves, and neurons. Since then, the company has expanded its pipeline and continues to invest significantly in the research and development of innovative therapies. Business model: Oyster Point Pharma has developed an innovative business model based on the development of therapies for eye diseases. The company utilizes its proprietary technology platform to identify new molecular targets and develop effective therapeutic options. The company works closely with leading scientists and clinics to develop and validate its pipeline of therapies. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Segments: Oyster Point Pharma focuses on developing innovative therapies for eye diseases. The company currently has three main products in its pipeline: OC-01, OC-02, and OC-03. OC-01 is a nasal spray based on the stimulation of tear flow. The product is currently in phase 3 clinical development for the treatment of patients with dry eye. Treatment with OC-01 is intended to increase the production and flow of tear fluid, thus relieving symptoms such as dryness, itching, and pain. OC-02 is a gel based on the stimulation of corneal nerves. The product is currently in phase 2 clinical development for the treatment of patients with neurotrophic keratitis. Treatment with OC-02 is intended to promote the regeneration of corneal nerves and accelerate the healing of the cornea. OC-03 is a nasal spray based on the stimulation of neurons in the nasal and oral areas. The product is currently in the preclinical development phase for the treatment of patients with acute glaucoma and has not yet been approved for use in humans. Products: Oyster Point Pharma currently has three main products in its pipeline: OC-01, OC-02, and OC-03. These products aim to develop innovative therapies for various eye diseases. The products utilize proprietary technologies to selectively stimulate tear flow, corneal nerves, and neurons. By developing these innovative therapies, the company aims to improve the vision and quality of life of patients. Summary: Oyster Point Pharma is an innovative biopharmaceutical company focused on the development of therapies for eye diseases. The company has developed a proprietary technology platform for the identification of new molecular targets and the development of effective therapeutic options. The company currently has three main products in its pipeline, aiming to develop innovative therapies for various eye diseases. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Oyster Point Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Oyster Point Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Oyster Point Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Oyster Point Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Oyster Point Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Oyster Point Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Oyster Point Pharma stock

What is the price-to-earnings ratio of Oyster Point Pharma?

The price-earnings ratio of Oyster Point Pharma is currently -5.58.

How has the price-earnings ratio of Oyster Point Pharma changed compared to last year?

The price-to-earnings ratio of Oyster Point Pharma has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Oyster Point Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Oyster Point Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Oyster Point Pharma affect the company?

An increase in the price-earnings ratio of Oyster Point Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Oyster Point Pharma affect the company?

A decrease in the price-earnings ratio of Oyster Point Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Oyster Point Pharma?

Some factors that influence the price-earnings ratio of Oyster Point Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Oyster Point Pharma pay?

Over the past 12 months, Oyster Point Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oyster Point Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Oyster Point Pharma?

The current dividend yield of Oyster Point Pharma is .

When does Oyster Point Pharma pay dividends?

Oyster Point Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oyster Point Pharma?

Oyster Point Pharma paid dividends every year for the past 0 years.

What is the dividend of Oyster Point Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oyster Point Pharma located?

Oyster Point Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oyster Point Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oyster Point Pharma from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Oyster Point Pharma pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Oyster Point Pharma in the year 2023?

In the year 2023, Oyster Point Pharma distributed 0 USD as dividends.

In which currency does Oyster Point Pharma pay out the dividend?

The dividends of Oyster Point Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oyster Point Pharma

Our stock analysis for Oyster Point Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oyster Point Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.